Anvatabart opadotin by Ambrx Biopharma for Gastric Cancer: Likelihood of Approval

Anvatabart opadotin is under clinical development by Ambrx Biopharma and currently in Phase I for Gastric Cancer.

Acutus will cut 70% of employees to meet Medtronic obligations

Listen to the article 4 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: Acutus Medical said Wednesday that

December 6, 2024

Insmed encourages people to ‘Speak Up’ in new marketing effort

Insmed wants to recognize patients who feel unseen or ignored, publishing a new survey, hosting a panel discussion with celebrity participants and debuting a new

March 2, 2024

Leap Therapeutics treks toward pivotal study in colorectal cancer, drops gastric cancer

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

January 29, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.